# CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage

> **NCT05333874** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 34 (estimated)

## Conditions studied

- Breast Cancer, Early-Onset

## Interventions

- **DRUG:** Neoadjuvant chemotherapy administered before surgical extraction of a tumor
- **OTHER:** Observational

## Key facts

- **NCT ID:** NCT05333874
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-04-06
- **Primary completion:** 2027-11-28
- **Final completion:** 2027-11-28
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05333874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05333874, "CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05333874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*